Payment overview · 2025
General Payments
$218.14
10 reported records · 6 companies
Healthcare provider profile · identity verified
Satyendra P Singh, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAKEWOOD, NJ · NPI 1811907108
Verified facts
What the public records show
CMS Open Payments records show Satyendra P Singh, MD received $218.14 in general payments during 2025 across 10 reported records.
AstraZeneca Pharmaceuticals LP accounted for 63.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Rybelsus by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $138.33 | 63.4% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.58 | 8.5% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $17.04 | 7.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.29 | 7.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.13 | 6.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.77 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $218.14 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $123.12 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $93.19 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 86 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 596 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 511 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 429 | 131 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 349 | 126 |
| Metformin Hcl | Metformin Hcl | 340 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 271 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 254 | 91 |
| Losartan Potassium | Losartan Potassium | 235 | 78 |
| Furosemide | Furosemide | 230 | 73 |
| Lisinopril | Lisinopril | 216 | 65 |
| Eliquis | Apixaban | 193 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 175 | 105 |
| Pravastatin Sodium | Pravastatin Sodium | 171 | 53 |
| Carvedilol | Carvedilol | 154 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 50 |
| Glimepiride | Glimepiride | 143 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 141 | 45 |
| Valsartan | Valsartan | 140 | 36 |
| Metformin Hcl Er | Metformin Hcl | 129 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 39 |
| Potassium Chloride | Potassium Chloride | 121 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 39 |
| Simvastatin | Simvastatin | 115 | 27 |
| Sertraline Hcl | Sertraline Hcl | 112 | 34 |
| Alprazolam | Alprazolam | 110 | 28 |
| Trazodone Hcl | Trazodone Hcl | 108 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 44 |
| Gabapentin | Gabapentin | 94 | 24 |
| Ezetimibe | Ezetimibe | 89 | 34 |
| Jardiance | Empagliflozin | 86 | 16 |
| Montelukast Sodium | Montelukast Sodium | 84 | 24 |
| Nifedipine Er | Nifedipine | 81 | 26 |
| Allopurinol | Allopurinol | 74 | 21 |
| Xarelto | Rivaroxaban | 71 | 21 |
| Entresto | Sacubitril/Valsartan | 70 | 19 |
| Repaglinide | Repaglinide | 69 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 18 |
| Levetiracetam | Levetiracetam | 68 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 67 | 21 |
| Januvia | Sitagliptin Phosphate | 67 | 14 |
| Methylprednisolone | Methylprednisolone | 67 | 56 |
| Omeprazole | Omeprazole | 61 | 21 |
| Mounjaro | Tirzepatide | 56 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 18 |
| Memantine Hcl | Memantine Hcl | 54 | 15 |
| Alendronate Sodium | Alendronate Sodium | 49 | 21 |
| Mirtazapine | Mirtazapine | 49 | 15 |
| Finasteride | Finasteride | 47 | 13 |
| Donepezil Hcl | Donepezil Hcl | 42 | suppressed |
| Rybelsus | Semaglutide | 41 | 13 |
| Glipizide Er | Glipizide | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 12 |
| Risperidone | Risperidone | 39 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | 22 |
| Pregabalin | Pregabalin | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | 13 |
| Divalproex Sodium | Divalproex Sodium | 37 | suppressed |
| Prednisone | Prednisone | 36 | 19 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | 14 |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 31 | 31 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 31 | 11 |
| Levoxyl | Levothyroxine Sodium | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | 16 |
| Olanzapine | Olanzapine | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Ramipril | Ramipril | 27 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | 11 |
| Irbesartan | Irbesartan | 26 | 11 |
| Klor-Con 10 | Potassium Chloride | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Xofluza | Baloxavir Marboxil | 21 | 20 |
| Atenolol | Atenolol | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Restasis | Cyclosporine | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 18 |
| Famotidine | Famotidine | 19 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 19 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 16 |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Linzess | Linaclotide | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Tymlos | Abaloparatide | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $218.14 · 10 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, JARDIANCE, Kerendia, Ozempic, Rybelsus, The Cologuard Plus Collection Kit | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error